Prostate cancer: Diagnosis, treatment, and experience at one tertiary- care military medical center, 1989 and 1994

Military Medicine

Volumn 161, Issue 11, 1996, Pages 646-653

  Bauer, John J ^b   Mcleod, David G ^b   Moul, Judd W ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; FLUTAMIDE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER DIAGNOSIS; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CRYOTHERAPY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MILITARY MEDICINE; MULTIMODALITY CANCER THERAPY; ORCHIECTOMY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME;

EID: 0029955483     PISSN: 00264075     EISSN: None     Source Type: Journal    
DOI: 10.1093/milmed/161.11.646     Document Type: Article

References (47)

1. Boring CC, et al: Cancer statistics 1994. CA Cancer J Clin 1994; 44: 7-26.
2. Carter HB, et al: The prostate: an increasing medical problem. Prostate 1990; 16: 39-50.
3. Lu-Yao GL, et al: An assessment of radical prostatectomy: time trends, geographical variation and outcomes. JAMA 1993; 269: 2633-6.
4. Wasson JH, et al: A structured literature review of treatment for localized prostate cancer. Arch Farm Med 1993; 2: 487-93.
5. Issacs JT: Importance of the natural history of benign hyperplasia to the evaluation: pharmacologic intervention. Prostate 1990; 3: 1-7.
6. Oesterling JE: Prostate-specific antigen: improving its ability to diagnose early prostate cancer. JAMA 1992; 267: 2236-8.
7. Morgan TO, et al: Age-specific reference ranges for prostate specific antigen: based detection of prostate cancer in African-American men N Engl J Med 1996; 335: 305-10.
8. Carter HB, et al: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215.
9. Benson MC, et al: Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992; 147: 815-6.
10. Benson MC, et al: The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992, 147. 817-21.
11. Seaman E, et al: Prostate specific density (PSAD): role in patient evaluation and management. Urol Clin North Am 1993; 20: 653-63.
12. Gleason DF: Histologic grading and clinical staging of prostate carcinoma. In Urologic Pathology. The Prostate, pp 171-97. Edited by Tannenbaum M. Philadelphia, Lea & Febinger, 1977
13. Mostofi FK, Sesterhemn IA, Szobin LH: Histologic Typing of Prostate Tumors. Geneva, Switzerland, World Health Organization, 1980.
14. Oboui M, et al: The American Joint Committee on Cancer and International Union Against Cancer. TNM classification of prostate cancer. Cancer 1994; 73: 104-14.
15. Huncharek M, et al: Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer Cancer Invest 1995; 13: 31-5.
16. Onik GM, et al: Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer 1993; 72: 1291-9.
17. Chodak GW, et al: Cryosurgery of the prostate revisited. Cancer 1993; 72: 1145.
18. Chodak GW, et al: Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330: 242-8.
19. Albertson PC, et al: Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995, 274: 626-31
20. Stamey TA, et al: The value of serial prostate antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. J Urol 1993; 150: 1056-9.
21. Schmidt HP, et al: Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing size Cancer 1993; 71: 2031-40.
22. Paulson DF, et al: Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 1982; 128: 502
23. Bagshaw MA, et al. Control of prostate cancer with radiotherapy: long-term results. J Urol 1994; 152: 1781-5.
24. Hanks GE, et al: Early prostate cancer: the national results of radiation treatment from the Patterns of Care and Radiation Therapy Oncology Group studies with prospects for improvement with conformational radiation and adjuvant androgen deprivation. J Urol 1994; 152: 1775-80.
25. Gibbons RP, et al: Total prostatectomy for clinically localized prostate cancer long-term results J Urol 1989; 141: 654-66.
26. Catalona WJ, Basler JW: Return of erections and urinary incontinence following nerve-sparing radical retropubic prostatectomy. J Urol 1993; 150: 905-7.
27. Fowler FJ, et al: Patient-reported complications and follow-up treatment after radical prostatectomy - the national medicine experience: 1988-1990 (updated June 1993). Urology 1993; 42: 622-9.
28. Jonler M, et al. Sequelae of radical prostatectomy. Br J Urol 1994; 74: 352-8.
29. Geary ES, et al: Nerve sparing radical prostatectomy: a different view. J Urol 1995; 154: 145-9.
30. Moul JW: An important goal of prostatectomy: minimizing incontinence. Contemp Urol 1994; 6: 15.
31. Moul JW: For incontinence after prostatectomy, tap a diversity of treatments. Contemp Urol 1994; 6: 78.
32. Pilepich MV, et al: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995; 45: 616-23.
33. Crawford DA, et al: A controlled trial of leuprolide with and without flutamide in prostate cancer. N Engl J Med 1989; 321: 848-53.
34. Denis LJ, et al. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology 1993; 42. 119-29.
35. Janknegt RA, et al: Orchlectomy and nilutamide or placebo as treatment of metastatic prostate cancer in a multinational double-blind randomized trial. J Urol 1993; 149: 77-83.
36. Goldberg SL, et al: Intermittent androgen suppression in the treatment of prostate cancer. J Urol 1994; 151: 240A.
37. Moul JW, Srivastava S, Mcleod DG: Molecular implications of the antiandrogen withdrawal syndrome. Semin Urol 1995; 13: 157.
38. Robinson RG: Strontium-89: precusor targeted therapy for pain of blastic metastatic disease. Cancer 1993; 72: 3433-5.
39. Eisenberger MA: Chemotherapy for prostate carcinoma. J Natl Cancer Inst Monograph 1988; 7: 151-63.
40. Pienta KJ, et al: Phase II evaluation of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate. J Clin Oncol 1994; 12: 2005-12.
41. Catalona WJ, et al: Increased specificity of PSA screening through the measurement of percent free PSA in serum. J Urol 1995; 153: 312A.
42. Parun AW, et al: Measurements of the ratio of free PSA to total PSA improves prostate cancer detection for men with total PSA levels between 4 0-10.0 ng/ml. J Urol 1995; 153: 295A.
43. Partin AW, et al: Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 1995; 45: 831-8.
44. Katz AE, et al: Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 1994; 43: 765-75.
45. Bauer JJ, et al: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer patients. J Urol 1996; 156: 1511-6.
46. Srivastava S, et al: Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation. Urology 1995, 46: 843-8.
47. Thompson TC, et al: A role for p53 in prostate cancer metastasis in the mouse prostate reconstruction model system. J Cell Biol Suppl D 1995; 18: 225 (abstract 107).